Company profile

Kriya Therapeutics

Kriya Therapeutics, founded in 2019, has raised $921.3 million across Seed, Series A, Series B, Series C, and Series D funding rounds, reaching a $2 billion valuation. Its largest round was a $386.3 million Series D in 2023 led by Bain Capital Life Sciences. Kriya Therapeutics develops gene therapies targeting chronic diseases, with a focus on liver and ocular indications. Backed by leading life sciences investors, the company is advancing multiple clinical programs with the goal of delivering long lasting gene based treatments.

Back to profiles

Quick facts

Total funding: $921.3 million
Valuation: $2 billion
Founded: 2019

Notable investors

Bain Capital Life Sciences

Reach buyers like Kriya Therapeutics on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like Kriya Therapeutics
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like Kriya Therapeutics.

The 14-day trial ships every feature, no card required.

Start free →